Carbidopa

Carbidopa

Clinical data
Trade names	Lodosyn
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN US FDA: Carbidopa
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Protein binding	76%
Metabolism	7 metabolites known, not metabolized extensively
Elimination half-life	2 hours
Identifiers
IUPAC name (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
CAS Number	28860-95-9 Y
PubChem CID	34359
IUPHAR/BPS	5159
DrugBank	DB00190 Y
ChemSpider	31640 Y
UNII	KR87B45RGH
KEGG	D00558 Y
ChEBI	CHEBI:39585 Y
ChEMBL	ChEMBL1201236 N
CompTox Dashboard (EPA)	DTXSID4022735
ECHA InfoCard	100.044.778
Chemical and physical data
Formula	C10H14N2O4
Molar mass	226.232 g·mol−1
3D model (JSmol)	Interactive image
Melting point	203 to 205 °C (397 to 401 °F)
SMILES O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C
InChI InChI=1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1 Y Key:TZFNLOMSOLWIDK-JTQLQIEISA-N Y
NY (what is this?)  (verify)

Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. This property is significant in that it allows a greater proportion of administered levodopa to cross the blood–brain barrier for central nervous system effect, instead of being peripherally metabolised into substances unable to cross said barrier.